Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Alpine Immune Sciences Earnings Perspective: Return On Capital Employed

Alpine Immune Sciences (NASDAQ:ALPN) brought in sales totaling $4.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 12.4%, resulting in a loss of $15.17 million. Alpine Immune Sciences collected $8.52 million in revenue during Q3, but reported earnings showed a $13.49 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.